OrthoTrophix Completed Subject Enrollment Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis

OAKLAND, Calif., May 21, 2015 /PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company completed subject enrollment and all scheduled dosing in its Phase 2 clinical study of TPX-100 in subjects with bilateral osteoarthritis (OA) of the knee. The Company initiated the study in early 2014 (Press Release on February 20, 2014). One hundred fifteen (115) subjects have completed all scheduled intra-articular injections. The last subject's last visit of the clinical site is scheduled in April 2016, and the study results are expected in mid-2016.

The Phase 2 clinical trial is entitled, "A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects with Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees." The study is designed to obtain proof of principle of safety and efficacy of TPX-100 for knee cartilage repair and regeneration compared to placebo among subjects with mild to moderate osteoarthritis. The study outline is posted at the ClinicalTrials.gov site.

OrthoTrophix is developing TPX-100 as the first disease modifying osteoarthritis drug (DMOAD).  Osteoarthritis (OA) is among the most common of all disabling diseases. In the US, it is estimated that more than 27 million people suffer from osteoarthritis, including more than half of individuals 65 years of age or older. The knee is the joint most affected by symptomatic OA, and is one of the most important causes of poor quality of life in the aging population.

The Company's Chief Medical Officer, Dawn McGuire, M.D., FAAN stated, "We have 18 clinical sites executing the study with rigor and enthusiasm.  We are encouraged that enrollment has been quite efficient, and that all 115 subjects have completed dosing with excellent safety and tolerability.  We look forward to one-year data in order to assess the efficacy of TPX-100 in knee cartilage repair and regeneration."

About OrthoTrophix, Inc.

OrthoTrophix, Inc., based in Oakland, Calif., is a privately held biopharmaceutical company focused on the development and commercialization of revolutionary therapeutics for the treatment of diseases and conditions involving the hard tissues. Founded by three co-founders in 2011, the primary focus of OrthoTrophix has been regeneration and repair of cartilage in the knee and other joints with its novel proprietary compounds which promote formation of new cartilage and bone tissues thereby repairing the respective defects. OrthoTrophix has received over $14 million from its Series A preferred stock financing and research and development revenues since its inception.

This press release contains "forward-looking" statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. OrthoTrophix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect OrthoTrophix' business.

Company Contact
Yoshi Kumagai
President and CEO
Tel:  (510) 488-3824
Fax:  (510) 567-8785

Logo - http://photos.prnewswire.com/prnh/20140220/SF68860LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orthotrophix-completed-subject-enrollment-of-the-phase-2-clinical-trial-of-a-new-cartilage-repair-therapeutic-for-knee-osteoarthritis-300087517.html

SOURCE OrthoTrophix, Inc.